164 results about "Nervous disease" patented technology

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and / or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy / asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

The invention provides nucleic acids encoding Delta3 proteins. Also provided are derivatives of Delta3 nucleic acids, polypeptides encoded thereby, and antibodies. Delta3 therapeutics, which are either antagonists or agonists of a Delta3 activity and which are capable of modulating the growth and / or differentiation of a cell, e.g., endothelial cell, are also provided herein. Furthermore, methods for treating or preventing diseases associated with an aberrant Delta3 activity and / or associated with abnormal cellular growth and / or differentiation, e.g., neurological disease or vascular disease, such as Agenesis of the Corpus Callosum with Peripheral Neuropathy (ACCPN), as well as diagnostic methods for detecting these diseases are disclosed.

An efficient, objective testing method and system for evaluating changes in mental function is described. The method and system are based on measuring an individual's behavioral responses and brain function during a brief cognitive test battery and passive control conditions. The method and system is designed to assess an individual's fundamental cognitive functions, and whether those functions have been significantly affected by a variety of factors such as progressive disease processes, medication, stress, fatigue, training, or the passage of time. The method and system can be used to determine whether drugs being evaluated to treat diseases or conditions affecting cognitive brain function have a significant positive effect on delaying or improving the symptoms of such a disease or condition, especially during clinical trials for drug approval and subsequent marketing. The method and system may also be employed as part of the successful diagnosis or ongoing treatment of neurological diseases or conditions that directly or indirectly affect human neurocognitive performance. The method and system may also be used to determine transitory changes in overall cognitive function due to emotional stress or fatigue, and more long lasting changes in overall cognitive function following training and educational programs.

The present invention relates to placenta tissue-derived multipotent stem cells and cell therapeutic agents containing the same. More specifically, to a method for producing placenta stem cells having the following characteristics, the method comprising culturing amnion, chorion, decidua or placenta tissue in a medium containing collagenase and bFGF and collecting the cultured cells: (a) showing a positive immunological response to CD29, CD44, CD73, CD90 and CD105, and showing a negative immunological response to CD31, CD34, CD45 and HLA-DR; (b) showing a positive immunological response to Oct4 and SSEA4; (c) growing attached to plastic, showing a round-shaped or spindle-shaped morphology, and forming spheres in an SFM medium so as to be able to be maintained in an undifferentiated state for a long period of time; and (d) having the ability to differentiate into mesoderm-, endoderm- and ectoderm-derived cells. Also the present invention relates to placenta stem cells obtained using the production method. The inventive multipotent stem cells have the ability to differentiate into muscle cells, vascular endothelial cells, osteogenic cells, nerve cells, satellite cells, fat cells, cartilage-forming cells, osteogenic cells, or insuline-secreting pancreatic β-cells, and thus are effective for the treatment of muscular diseases, osteoporosis, osteoarthritis, nervous diseases, diabetes and the like, and are useful for the formation of breast tissue.

The present invention relates to a method for treating nerve disorders in a mammal or a vertebrate by administering a TNF-alpha inhibitor. The invention also relates to the use of a TNF-alpha inhibitor in the preparation of pharmaceutical compositions for the treatment of nerve root injury and other nerve disorders.

Computer controlled methods, systems and apparatus for detecting an infectious agent in a host cell, an animal cell, or plant cell, a body fluid or tissue sample to provide information useful to diagnose a disease or prognosticate disease susceptibility, extent or outcome are provided. In one illustrative embodiment, the infected animal cell is a Chlamydia infected mononuclear phagocyte in a blood sample. In another illustrative embodiment, the infected body fluid is a blood sample infected with “fee floating”Chlamydia. Detection and preferably, quantification of such an infected mononuclear phagocyte(s) or blood sample provides information useful in diagnosing or prognosticating susceptibility, extent or outcome of patients suspected of suffering from vascular, coronary or central nervous disease(s) or disorder(s).

The invention relates to medicinally used substances which specifically inhibit peptidases splitting Gly-Pro-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic composition containing at least one such substance for preventing or treating diseases, particularly diseases with an overshooting immune response (autoimmune diseases, allergies, and transplant rejections), other chronic inflammatory diseases, neuronal diseases, brain damages, skin diseases (acne and psoriasis, among others), tumor diseases, and special viral infections (including SARS).

The invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates and stereoisomers thereof, wherein A, B, E, G, W, X, Y, Z, o, and R1 are as disclosed herein (“Compound(s) of the Invention”), which are useful as cardio-protective and / or neuro-protective agents. The invention also provides pharmaceutical compositions comprising a Compound of the Invention and methods for treating, preventing and / or managing a vascular, cardiovascular or neurological disease or disorder, comprising administering to a patient in need thereof a Compound of the Invention.

The invention discloses the structure of four novel bakkenolide compounds extracted from Petasites tricholobus Franch. having a formula (1), the process for extraction and separation, and the use of the compounds in preparing medicament for the treatment and prevention of diseases possibly related to theramine and / or leukotrienes constituents, including asthma, allergic rhinitis, nasal sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, chronic infectious arthritis, enteropathy, nervous disease and otitis.

The invention provides methods for treating or preventing cardiac and neurological disorders using chemokine receptor antagonists.

Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease.

The present invention relates to a novel class of substituted phenylpiperazinyl derivatives having the formula (I) wherein X, Z, Y, U,V, Alk, W, R<1> , R<2>, R<3>, R<11>, R<12>, R<13> n, m and the dotted line are as defined in the description. The compounds of the invention are dopamine D4 receptor ligands and are therefore useful for the treatment of certain psychiatric and neurologic disorders, including psychosis.

The present invention discloses an application of flavone compound or its derivative in preparation of medicine for curing psychic disease and nervous disease. Said invention also discloses a medicine composition containing flavone compound or its derivative. Said invention also provides an excitant of dopamine transport protein firstly, and the tests show that the dopamine transport protein can be excited.

The invention provides transcranial electrostimulation by combining transcranial direct current stimulation (tDCS) and theta burst stimulation (TBS) to achieve an unexpected therapeutic effect in various brain or neural diseases. Accordingly, the invention provides a mode of direct current with biphasic square wave pulses in the treatment of brain or neural diseases. Also provided are methods of employing the transcranial electrostimulation of the invention and applications of the transcranial electrostimulation of the invention.

A Chinese medicine for treating the diabetic peripheral neuropathy is prepared from 13 Chinese-medicinal materials including astragalus root, rehmannia root, Chuan-xiong rhizome, Chinese angelica root, etc. Its preparing process is also disclosed.

The present invention relates to novel tricyclic compounds useful for the treatment of inflammatory conditions, diseases of the central nervous and insulin resistant diabetes.

The invention discloses a restructured fusion protein PTD-MAX, the amino acid sequence of which is shown in SEQ ID NO: 6, and the coding nucleotide sequence of which is shown in SEQ ID NO: 4. The restructured fusion protein PTD-MAX not only has the biologic activity of maxadilan of a specific agonist of PAC1 receptor, but also has the function of trans-cell membrane conveying, can effectively enter cells, penetrates a blood brain barrier, acts on the central nervous system, and has more remarkable effect of inhibiting feeding behavior for a long time than maxadilan. The restructured fusion protein PTD-MAX confers the function of trans-cell membrane conveying of PTD to Maxadilan, thus leading the Maxadilan to penetrate the blood brain barrier and a cornea more easily, greatly improving theapplication value thereof in nervous diseases of brain and eyes, and being capable of improving the ways of application and application range thereof.

A compound represented by the general formula (I-a):[wherein R1a and R2a each means hydrogen, lower cycloalkyl, lower alkyl, etc.; R3a means hydrogen, lower cycloalkyl, lower alkyl, etc.; R4a and R5a each means lower alkyl, lower cycloalkyl, etc. or R4a and R5a are bonded to each other to form lower cycloalkylidene; and R6a means lower alkyl, lower haloalkyl, etc.]. This compound functions as an LCE inhibitor and is useful as a therapeutic agent for various circulatory diseases, nervous diseases, metabolic diseases, reproductive diseases, digestive tract diseases, neoplasm, infectious diseases, etc.

The invention relates to an herbal composition comprising extract of plant Moringa Oleifera, a member of family Moringaceae, plant Piper Nigrum, a member of family Piperaceae and plant Nicotiana Tabacum, a member of family Solanaceae for treating or alleviating of vascular headaches, neurological conditions and neurodegenerative diseases. The invention also reveals a method of preparing and using the composition.

The present invention relates to a novel use of an α1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in α1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous disease model for human nervous related diseases such as novelty-seeking character, alcoholism, anxiety and emotion disorder by stress, etc. The α1G T-type channel transgenic mice showing novelty-seeking and alcohol preference of the present invention can be effectively used for the development of a medicine and a therapeutic method for human nervous diseases.

The invention relates to a phenyl ring-aromatic ring cascaded micro-molecular organic compound which can be used as a protein-tyrosine-phosphatase subtype inhibitor and is shown in a general formula I as described in the specification. The compound can be used as a tool compound for research on the biological functions of a variety of subtypes of a protein-tyrosine-phosphatase family in cell signal transduction, so novel means is provided for prevention and treatment of cancers, metabolism and immunological diseases, cardiovascular diseases and nervous diseases. The invention also relates to a preparation method and medicinal application of the compound.

Compounds of the formulaand pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and / or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy / asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

A novel family of mammalian catecholamine proteins is identified. These proteins are useful in methods of diagnosing neurological diseases, including schizophrenia and bipolar disease, as well as cardiovascular disease. This family of CRP40 proteins are also useful to treat neurological diseases.

The present invention relates to a compound having a blocking effect against sodium ion channels, particularly Nav1.7, a preparation method thereof and use thereof. The compound represented by the Formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof can be effectively used in the prevention or treatment of pains, for example, acute pain, chronic pain, pain from nervous disease, postoperative pain, migraine, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neuropathic disease, epilepsy, arrhythmia, myotonia, ataxia, multiple sclerosis, irritable bowel syndrome, urinary incontinence, visceral pain, depression, erythromelalgia, paroxysmal extreme pain disorder (PEPD).

Disclosed is a composition for protecting nerve cells, promoting nerve cell growth and regenerating nerve cells comprising berberine, derivatives thereof or pharmaceutically acceptable salts thereof. The composition has protective effects against apoptosis of neuronal stem cells and differentiated neuronal stem cells, an effect of inducing the regeneration of nerve cells, a regenerative effect on neurites, a neuroregenerative effect on central nerves and peripheral nerves, a reformation effect on neuromuscular junctions, and a protective effect against apoptosis of nerve cells and a neuroregenerative effect in animals suffering from dementia and brain ischemia. Therefore, the composition can be used as a therapeutic agent for the prevention and treatment of neurodegenerative diseases, ischemic nervous diseases or nerve injuries, and for the improvement of learning capability.

The present invention relates to a novel use of an α1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in α1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous disease model for human nervous related diseases such as novelty-seeking character, alcoholism, anxiety and emotion disorder by stress, etc. The α1G T-type channel transgenic mice showing novelty-seeking and alcohol preference of the present invention can be effectively used for the development of a medicine and a therapeutic method for human nervous diseases.